Common name
(3S)-tetrahydrofuran-3-ol
IUPAC name
(3S)-tetrahydrofuran-3-ol
SMILES
O1CCC(C1)O
Common name
(3S)-tetrahydrofuran-3-ol
IUPAC name
(3S)-tetrahydrofuran-3-ol
SMILES
O1CCC(C1)O
INCHI
InChI=1S/C4H8O2/c5-4-1-2-6-3-4/h4-5H,1-3H2/t4-/m0/s1
FORMULA
C4H8O2
Common name
(3S)-tetrahydrofuran-3-ol
IUPAC name
(3S)-tetrahydrofuran-3-ol
Molecular weight
88.105
clogP
0.839
clogS
0.178
Frequency
0.0031
HBond Acceptor
2
HBond Donor
1
Total PolarSurface Area
29.46
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00130 | Cladribine |
|
Antineoplastic Agents; Immunosuppressive Agents; Antimetabolites; Purine analogues; Antineoplastic and Immunomodulating Agents; | For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma. |
| FDBD00137 | Idoxuridine |
|
Antiviral Agents; Nucleic Acid Synthesis Inhibitors; Ophthalmologicals; Sensory Organs; Antiinfectives for Systemic Use; Dermatologicals; Direct Acting Antivirals; Antivirals for Systemic Use; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Antiinfectives; | For use in keratoconjunctivitis and keratitis caused by herpes simplex virus. |
| FDBD00208 | Floxuridine |
|
Antineoplastic Agents; Immunosuppressive Agents; Antimetabolites, Antineoplastic; | For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion). |
| FDBD00309 | Trifluridine |
|
Antineoplastic Agents; Antiviral Agents; Antimetabolites; Antineoplastic and Immunomodulating Agents; Ophthalmologicals; Sensory Organs; Antiinfectives; Pyrimidine Analogues; | Ophthalmic solution for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. |
| FDBD00419 | Pentostatin |
|
Antineoplastic Agents; Immunosuppressive Agents; Adenosine Deaminase Inhibitors; Antibiotics; Antineoplastic and Immunomodulating Agents; | For the treatment of hairy cell leukaemia refractory to alpha interferon. |
| FDBD01104 | Decitabine |
|
Antineoplastic Agents; Enzyme Inhibitors; Antimetabolites; Antimetabolites, Antineoplastic; Teratogens; Antineoplastic and Immunomodulating Agents; Pyrimidine Analogues; | For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores |
| FDBD01575 | Afatinib |
|
Antineoplastic Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; | Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. |
| FDBD01639 | Empagliflozin |
|
Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins; | Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. |
| FDBD02548 | furyloxyfen |
|
Herbicide | Herbicide |
9 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 2py4_ligand_frag_1.mol2 | 2py4 | 1 | -6.17 | C1C[C@@H](CO1)O | 6 |
| 3ehw_ligand_frag_1.mol2 | 3ehw | 1 | -6.14 | C1C[C@@H](CO1)O | 6 |
| 2yay_ligand_frag_1.mol2 | 2yay | 1 | -6.05 | C1C[C@@H](CO1)O | 6 |
| 4uxh_ligand_frag_2.mol2 | 4uxh | 1 | -6.05 | C1OCC[C@@H]1O | 6 |
| 2yb0_ligand_frag_1.mol2 | 2yb0 | 1 | -6.00 | C1C[C@@H](CO1)O | 6 |
| 2yaz_ligand_frag_1.mol2 | 2yaz | 1 | -5.99 | C1C[C@@H](CO1)O | 6 |
| 2qch_ligand_frag_1.mol2 | 2qch | 1 | -5.88 | C1C[C@@H](CO1)O | 6 |
| 2yof_ligand_frag_1.mol2 | 2yof | 1 | -5.88 | C1OC[C@H](C1)O | 6 |
152 ,
16
